Biotech

Pharma Elaine Chen

STAT Plus: Liver disease MASH is next target for obesity drugs in development

Adam's Take Adam Feuerstein

STAT Plus: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves

The Readout Meghana Keshavan

STAT Plus: What do CEOs owe the world?

Adam's Take Adam Feuerstein

STAT Plus: Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence

The Readout Damian Garde

STAT Plus: Novavax’s money is going in the wrong direction

Biotech Jason Mast

STAT Plus: Scientists take a (small) step toward universal antivenom

The Readout Damian Garde

STAT Plus: Actually Wegovy is good for dialysis companies, dialysis provider says

Biotech Jason Mast

STAT Plus: Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Pharma Matthew Herper

STAT Plus: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

The Readout Damian Garde

STAT Plus: Bayer, short on cash, reaches into shareholders’ pockets

Biotech Angus Chen

STAT Plus: In ‘major milestone,’ FDA approves first cell therapy for solid tumors

Biotech Allison DeAngelis

STAT Plus: Flagship Pioneering startup lays off a third of staff

Biotech Robert Weisman — Boston Globe

STAT Plus: Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

The Readout Damian Garde

STAT Plus: Alnylam thickened the plot

Biotech Jason Mast

STAT Plus: For unlucky mountaineers, tundra explorers, and the unhoused, a new drug could avert the ravages of frostbite

The Readout Damian Garde

STAT Plus: Pharma’s contractors might finally be on the rebound

Adam's Take Adam Feuerstein

STAT Plus: Gaming Amylyx stock reactions to the next ALS drug test, and a chat with CRISPR’s CEO about a new investor

Biotech Robert Weisman — Boston Globe

STAT Plus: The Jewish American and Palestinian American scientists who’ve been partnering for 14 years on science’s toughest challenges

The Readout Meghana Keshavan

STAT Plus: Replicate’s srRNA rabies vaccine effective in Phase 1

Biotech Allison DeAngelis

STAT Plus: Biotech launches with $135 million for Vertex-competing pain medicine

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Biogen Alzheimer’s drug launch off to slow start

The Readout Meghana Keshavan

STAT Plus: The need to know biotech news stories today

Biotech Allison DeAngelis

STAT Plus: Startup BioAge raises $170 million Series D for Zepbound combination therapy

Biotech Adam Feuerstein

STAT Plus: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study

Biotech Adam Feuerstein

STAT Plus: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease

The Readout Meghana Keshavan

STAT Plus: Psychedelic investment continues to ramp up

The Readout Meghana Keshavan

STAT Plus: Does Moderna’s RSV vaccine lose efficacy faster than others?

Adam's Take Adam Feuerstein

STAT Plus: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys

The Readout Damian Garde

STAT Plus: Gilead sours on the ‘don’t eat me’ business